10th Jun 2022 11:21
(Alliance News) - Renalytix PLC on Friday said a recent testing at Mount Sinai Health System showed clinical utility and care benefits of KidneyIntelX.
The London-based diagnostics company focused on kidney health said KidneyIntelX, a laboratory-developed test, was tested in 1,112 adult patients with diabetic kidney disease. In the study, more than half of KidneyIntelX prognostic tests were ordered by primary care physicians, followed by endocrinologists.
The utility data was presented on Monday at the American Diabetes Association in New Orleans.
Mount Sinai Clinical Director Joji Tokita said: "Before KidneyIntelX, we did not have a way to effectively predict which patients with early stage DKD are at higher risk for progressive loss of kidney function and kidney failure. Nearly 95% of patients with chronic kidney disease are in stages 1 through 3, but its progression is often asymptomatic until it progresses to end stages and the damage is often irreversible.
"I'm encouraged to see the real-world application of KidneyIntelX by my primary care colleagues, where we can follow guideline-based care to reduce patient risk early and change the trajectory of disease progression and costs."
Clinical utility study results are being prepared to be published in a peer reviewed publication in 2022.
Kidney disease is a public health epidemic affecting over 850 million people globally.
Renalytix shares were up 1.0% at 184.75 pence each on Friday morning in London.
By Xindi Wei; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc